Newsroom

CSL Behring Continues to Support Alpha 1 Community, Presents Exciting, New Drug Development Projects at 30th Anniversary of the European Respiratory Society International Congress

MARBURG, Germany - Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awarenes…

At White House Roundtable, Plasma Industry Leader & CSL CEO Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19

• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID…

CSL Behring’s Global Role in Battling COVID-19

Here is how CSL Behring is working around the world with academia, industry and governments to combat the novel coronavirus C…

CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress

KING OF PRUSSIA, Pa. • Five coagulation researchers named this year’s recipients • Professor Heimburger Awards and ISTH…

In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress

KING OF PRUSSIA, Pa. - Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment…

CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure

KING of PRUSSIA, Pa. • Unique gene therapy has the potential to be one of the first to market treatments to provide potent…

Yi Deng and Bill Mezzanotte Elected to University City Science Center Board of Directors

PHILADELPHIA

CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit

King of Prussia, Pa Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020